Edition:
United States

Oragenics Inc (OGEN.A)

OGEN.A on American Stock Exchange

0.66USD
1:45pm EST
Change (% chg)

$-0.00 (-0.75%)
Prev Close
$0.67
Open
$0.68
Day's High
$0.68
Day's Low
$0.65
Volume
6,245
Avg. Vol
16,214
52-wk High
$1.20
52-wk Low
$0.34

OGEN.A

Chart for OGEN.A

About

Oragenics, Inc. develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic... (more)

Overall

Beta: 1.90
Market Cap(Mil.): $32.66
Shares Outstanding(Mil.): 49.11
Dividend: --
Yield (%): --

Financials

  OGEN.A Industry Sector
P/E (TTM): -- 28.98 29.85
EPS (TTM): -0.19 -- --
ROI: -267.85 15.43 14.85
ROE: -267.85 16.63 16.28

BRIEF-Oragenics board authorized to increase authorized shares of stock from 100 mln shares to 250 mln shares

* Oragenics - board authorized to increase authorized shares of stock from 100 million shares to 250 million shares - sec filing Source text (http://bit.ly/2jNqM0P) Further company coverage:

Jan 13 2017

BRIEF-Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis

* U.S. FDA grants fast track designation for the development of Oragenics' AG013 for oral mucositis

Nov 21 2016

BRIEF-Oragenics - expects to file an investigational new drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017

* Oragenics - expects to file an investigational new drug (ind) update and initiate a phase 2 study with ag013 in united states and europe in early 2017

Nov 21 2016

BRIEF-Oragenics, Koski Family Limited partnership enters into amendment to June 30, 2016 unsecured promissory note

* Co and Koski Family Limited partnership entered into an amendment to June 30, 2016 unsecured promissory note - SEC filing

Sep 15 2016

BRIEF-Oragenics Inc files for stock shelf of upto $30 mln

* Files for stock shelf of upto $30 million - SEC filing Source text for Eikon: (http://bit.ly/2c7YEmI) Further company coverage:

Aug 25 2016

BRIEF-Oragenics announces receipt of payment in connection with sale of consumer probiotic biz

* Oragenics announces receipt of payment in full under promissory note in connection with sale of consumer probiotic business

Aug 01 2016

Earnings vs. Estimates